Lipodystrophy - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Lipodystrophy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Lipodystrophy - Pipeline Review, H2 2014', provides an overview of the Lipodystrophy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lipodystrophy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lipodystrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lipodystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lipodystrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lipodystrophy Overview 6
Therapeutics Development 7
Pipeline Products for Lipodystrophy - Overview 7
Pipeline Products for Lipodystrophy - Comparative Analysis 8
Lipodystrophy - Therapeutics under Development by Companies 9
Lipodystrophy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Lipodystrophy - Products under Development by Companies 13
Lipodystrophy - Companies Involved in Therapeutics Development 14
Aileron Therapeutics, Inc. 14
Ambrx, Inc. 15
AstraZeneca PLC 16
Bolder Biotechnology, Inc. 17
Theratechnologies Inc. 18
Zydus Cadila Healthcare Limited 19
Lipodystrophy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ALRN-5281 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ARX-328 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BBT-031 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
metreleptin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
saroglitazar - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
tesamorelin acetate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Lipodystrophy - Recent Pipeline Updates 39
Lipodystrophy - Dormant Projects 46
Lipodystrophy - Product Development Milestones 47
Featured News & Press Releases 47
May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn 47
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 47
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 48
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 48
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin 49
Sep 18, 2013: EMD Serono Notifies FDA of a Shortage of Tesamorelin 50
Jul 08, 2013: Theratechnologies Inc./Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized 50
Jun 28, 2013: Theratechnologies Provides Regulatory Update for Colombia 50
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin 51
May 07, 2013: Aileron Therapeutics Successfully Completes Stapled Peptide Clinical Trial 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Lipodystrophy, H2 2014 7
Number of Products under Development for Lipodystrophy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Lipodystrophy - Pipeline by Aileron Therapeutics, Inc., H2 2014 14
Lipodystrophy - Pipeline by Ambrx, Inc., H2 2014 15
Lipodystrophy - Pipeline by AstraZeneca PLC, H2 2014 16
Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H2 2014 17
Lipodystrophy - Pipeline by Theratechnologies Inc., H2 2014 18
Lipodystrophy - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Lipodystrophy Therapeutics - Recent Pipeline Updates, H2 2014 39
Lipodystrophy - Dormant Projects, H2 2014 46